profession
FDA approves first human embryonic stem cell trial
NEWS IN BRIEF — Posted Aug. 23, 2010
The Food and Drug Administration in late July gave Geron Corp., a biotech firm based in Menlo Park, Calif., approval to proceed with the first-ever phase I safety testing of an embryonic stem-cell-based therapy. Geron hopes its drug, which is injected into a patient's injured spinal cord lesion site, will help restore spinal cord functioning.
The FDA's decision came after the agency initially denied approval due to a Geron-conducted animal study that found a higher frequency of cysts in mice whose spinal cords were injected with the investigational therapy called GRNOPC1. Geron slightly changed the drug and performed additional animal testing to gain the FDA's approval for human clinical trials.
In 2001, President George W. Bush limited federal funding of embryonic stem cell research based on beliefs that the studies involved destroying human life. Last year, President Obama reversed the policy.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2010/08/23/prbf0823.htm.












